...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Microencapsulation: Microcapsules Liposomes Nanoparticles Microcells Microspheres >Salmon calcitonin-loaded Eudragit~R and Eudragit~R-PLGA nanoparticles: in vitro and in vivo evaluation
【24h】

Salmon calcitonin-loaded Eudragit~R and Eudragit~R-PLGA nanoparticles: in vitro and in vivo evaluation

机译：鲑鱼降钙素负载的Eudragit〜R和Eudragit〜R-PLGA纳米颗粒：体内和体外评估

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The main objective of this study was to prepare salmon calcitonin (sCT)-loaded Eudragit~RRSPO, Eudragit~RL100 and Eudragit~R-poly(lactic-co-glycolic acid) blend nanoparticles for in vitro and in vivo evaluation as an oral drug delivery system. The prepared nanoparticles ranged in size from 179.7 to 308.9 nm with a polydispersity index between 0.051 and 2.75, and had surface charges～-11 to +6 mV. Efficient sCT encapsulation and release was observed with all the nanoparticle formulations. The polymer type was an important factor that influenced the release characteristics and the in vivo hypocalcemic effect. Nanoparticle formulations were also prepared with sodium taurodeoxycholate (NaTDC) and characterized. No statistically significant difference was noted between the hypocalcemic effect of any of the nanoparticle formulations with and without NaTDC (p > 0.05). The use of Eudragit~RRSPO nanoparticles appears to be a potential approach for the oral delivery of sCT.
机译：这项研究的主要目的是制备鲑鱼降钙素（sCT）的Eudragit〜RRSPO，Eudragit〜RL100和Eudragit〜R-聚-乳酸-乙醇酸共混物纳米颗粒作为口服药物进行体外和体内评估输送系统。制备的纳米颗粒尺寸为179.7〜308.9nm，多分散指数在0.051〜2.75之间，表面电荷约为-11〜+ 6mV。在所有纳米颗粒制剂中均观察到有效的sCT包封和释放。聚合物类型是影响释放特性和体内降血钙作用的重要因素。还用牛磺脱氧胆酸钠（NaTDC）制备了纳米颗粒制剂并进行了表征。在有或没有NaTDC的任何纳米颗粒制剂的降血钙作用之间未发现统计学上的显着差异（p> 0.05）。 Eudragit〜RRSPO纳米颗粒的使用似乎是口服sCT的潜在方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号